LitAlert ~~ GeneLit.com

    • Combined breast conservation therapy versus mastectomy for BRCA mutation carriers – A systematic review and meta-analysis.
    • Davey MG, Davey CM, Ryan EJ, Lowery AJ, Kerin MJ.
    • Breast. 2021 Feb 4:S0960-9776(21)00015-1. doi: 10.1016/j.breast.2021.02.001. Epub ahead of print.
    • Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers.
    • Grill S, Yahiaoui-Doktor M, Basrai M, Struck J, Schulte J, Berling-Ernst A, Engel C, Ullrich M, Lammert J, Bischoff SC, Schmidt T, Niederberger U, Chronas D, Rhiem K, Schmutzler R, Halle M, Kiechle M.
    • Breast Cancer Res Treat. 2021 Feb 4. doi: 10.1007/s10549-020-06070-x. Epub ahead of print.
    • A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
    • Geenen JJ, Dackus GM, Schouten PC, Pluim D, Marchetti S, Sonke GS, Józwiak K, Huitema AD, Beijnen JH, Schellens JH, Linn SC.
    • Int J Cancer. 2021 Feb 4. doi: 10.1002/ijc.33498. Epub ahead of print.
    • Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
    • Chen Z, Wang X, Li X, Zhou Y, Chen K.
    • J Int Med Res. 2021 Feb;49(2):300060521991019. doi: 10.1177/0300060521991019.